Wall Street analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to report $522.89 million in sales for the current fiscal quarter, according to Zacks. Eight analysts have issued estimates for Jazz Pharmaceuticals’ earnings. The lowest sales estimate is $515.40 million and the highest is $530.00 million. Jazz Pharmaceuticals reported sales of $469.37 million during the same quarter last year, which indicates a positive year-over-year growth rate of 11.4%. The firm is expected to issue its next earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year sales of $2.11 billion for the current year, with estimates ranging from $2.09 billion to $2.15 billion. For the next financial year, analysts anticipate that the company will report sales of $2.32 billion, with estimates ranging from $2.22 billion to $2.39 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.16 by $0.49. The firm had revenue of $534.13 million during the quarter, compared to analyst estimates of $507.23 million. Jazz Pharmaceuticals had a net margin of 32.99% and a return on equity of 27.72%. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the business posted $3.49 EPS.

JAZZ has been the subject of a number of recent research reports. Barclays boosted their price objective on shares of Jazz Pharmaceuticals from $164.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. HC Wainwright restated a “hold” rating and issued a $147.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 8th. ValuEngine upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 8th. TheStreet upgraded shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Wednesday, July 24th. Finally, Royal Bank of Canada set a $184.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, July 3rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $174.14.

Shares of JAZZ traded up $0.92 during mid-day trading on Monday, reaching $135.75. The company’s stock had a trading volume of 357,873 shares, compared to its average volume of 567,082. The stock has a market cap of $7.69 billion, a PE ratio of 11.09, a P/E/G ratio of 1.08 and a beta of 1.14. The company has a current ratio of 3.71, a quick ratio of 3.52 and a debt-to-equity ratio of 0.58. Jazz Pharmaceuticals has a 52 week low of $113.52 and a 52 week high of $176.73. The company’s fifty day moving average price is $137.73 and its two-hundred day moving average price is $134.55.

In other Jazz Pharmaceuticals news, Director Catherine A. Sohn sold 726 shares of the business’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $135.65, for a total transaction of $98,481.90. Following the transaction, the director now directly owns 9,574 shares of the company’s stock, valued at approximately $1,298,713.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Paul Treacy sold 4,371 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $137.40, for a total transaction of $600,575.40. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of the business. Signaturefd LLC increased its position in Jazz Pharmaceuticals by 56.3% during the 2nd quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 72 shares during the period. Commonwealth Equity Services LLC increased its position in Jazz Pharmaceuticals by 2.8% during the 2nd quarter. Commonwealth Equity Services LLC now owns 3,338 shares of the specialty pharmaceutical company’s stock valued at $475,000 after purchasing an additional 92 shares during the period. MAI Capital Management increased its position in Jazz Pharmaceuticals by 2.2% during the 2nd quarter. MAI Capital Management now owns 4,364 shares of the specialty pharmaceutical company’s stock valued at $622,000 after purchasing an additional 96 shares during the period. MML Investors Services LLC increased its position in Jazz Pharmaceuticals by 4.4% during the 2nd quarter. MML Investors Services LLC now owns 2,593 shares of the specialty pharmaceutical company’s stock valued at $370,000 after purchasing an additional 109 shares during the period. Finally, Confluence Investment Management LLC increased its position in Jazz Pharmaceuticals by 2.9% during the 2nd quarter. Confluence Investment Management LLC now owns 4,243 shares of the specialty pharmaceutical company’s stock valued at $605,000 after purchasing an additional 118 shares during the period. 90.30% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: What is the operating income formula?

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.